{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T04:35:54Z","timestamp":1725856554382},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,9,7]],"date-time":"2005-09-07T00:00:00Z","timestamp":1126051200000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the antiviral efficacy and safety of switching from a protease inhibitor (PI) to nevirapine in patients with long\u2010term HIV\u20101 RNA suppression on PI\u2010containing regimens, and to assess its influence in the adherence to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In an open\u2010label multicentre study, 160 HIV\u2010infected patients with undetectable viral load for at least 6 months on a PI\u2010containing regimen were randomized to either continue with their PI regimen (<jats:italic>n<\/jats:italic>=79) or replace PI with nevirapine (<jats:italic>n<\/jats:italic>=81). Clinical assessment included plasma HIV\u20101 RNA, blood chemistry, haematology, lymphocyte counts and adverse events reports. Adherence to treatment and lipodystrophy syndrome were assessed by patient self\u2010reporting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment efficacy was equivalent in the two arms, for patients with viral loads either above or below 100 000 HIV\u20101 RNA copies\/mL. The increase in CD4 cell count was significant in both arms (<jats:italic>P<\/jats:italic>&lt;0.00001) but the average CD4 cell count at 48 weeks was slightly higher in the nevirapine arm (596 vs. 569; <jats:italic>P<\/jats:italic>=0.1588). The number of patients with severe hypertriglyceridaemia (&gt;400 mg\/dL) after 48 weeks of treatment decreased in the nevirapine arm (from 11 to six), but increased in the PI arm (from four to 11) and led to treatment discontinuation in two patients. Lipodystrophy changes increased in 15% of patients in the PI arm but decreased in 4% of patients in the nevirapine arm. Finally, although adherence was similar in the two arms, patients reported that it required significantly less effort to stay on treatment in the nevirapine arm.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results indicate that switching from PI to nevirapine is as effective as continuing with PI for maintaining viral control, even in patients with baseline viral load above 100 000 copies\/mL. In addition, reductions in hypertriglyceridaemia and lipodystrophy and in the effort required to stay on treatment were observed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2005.00320.x","type":"journal-article","created":{"date-parts":[[2005,9,7]],"date-time":"2005-09-07T13:32:39Z","timestamp":1126099959000},"page":"353-359","source":"Crossref","is-referenced-by-count":11,"title":["A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load"],"prefix":"10.1111","volume":"6","author":[{"given":"JA","family":"Arranz Caso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JC","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Castilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JP","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fern\u00e1ndez Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"G\u00f3rgolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,9,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.4065\/74.12.1284"},{"key":"e_1_2_5_4_2","first-page":"2093","article-title":"Diagnosis, prediction, and natural course of HIV\u20101 protease\u2010inhibitor\u2010associated lipodistrophy, hyperlipidaemia, and diabetes mellitus","volume":"353","author":"Carr A","year":"1999","journal-title":"a cohort study"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022048"},{"key":"e_1_2_5_6_2","first-page":"146","article-title":"Switch studies","volume":"3","author":"Murphy RL","year":"2002","journal-title":"A review"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200311210-00007"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200005050-00006"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/317424"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/324629"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00002030-199905070-00009","article-title":"Reversion of metabolic abnormalities after switching from HIV\u20101 protease inhibitors to nevirapine","volume":"13","author":"Mart\u00ednez E","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200207050-00010"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200112070-00008"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00126334-200107010-00003","article-title":"and the Spanish Lipodystrophy Group. Antiretroviral treatment simplification with nevirapine in protease inhibitor\u2010experienced patients with HIV\u2010associated lipodystrophy","volume":"27","author":"Ruiz L","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_5_15_2","first-page":"17","article-title":"Nevirapine to simplify HAART in PI\u2010experienced, successfully treated patients","author":"Maggiolo F","year":"2002","journal-title":"Sixth International Congress on Drug Therapy in HIV infection"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021589"},{"issue":"2","key":"e_1_2_5_17_2","first-page":"S177","article-title":"Determinants of virological response to antiretroviral therapy","volume":"30","author":"Deeks SG.","year":"2000","journal-title":"implications for long-term strategies"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/135965350200700205","article-title":"and the Tril\u00e8ge (Agence Nationale de Recherches sur le SIDA 072) Study Team. Adherence to antiretroviral therapy and outcomes in HIV\u2010infected patients enrolled in an induction\/maintenance randomized trial","volume":"7","author":"Flandre P","year":"2002","journal-title":"Antivir Ther"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.12.1376"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2005.00320.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2005.00320.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:59:24Z","timestamp":1696877964000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2005.00320.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1111\/j.1468-1293.2005.00320.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2005.00320.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}